News

This recap of skin cancer innovations accompanies the cover story of our May publication.

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.

While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.

These challenges may exacerbate racial inequities in care access and quality, according to a new study.

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.

Review Dermatology Times' coverage of Rosacea Awareness Month.

Dermatology Times is looking back on the top stories in dermatology from the month of April.

A decision from the FDA is expected in the second half of 2024.

Dermatology Times is recapping our top expert interviews from the month of April.

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.

A study found that in addition, recovery time was both quick and yielded minimal symptoms.

The FDA’s PDUFA date is expected in quarter 4 of 2024.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.

ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union's approval of bimekizumab for HS, and more.

Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.

Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.

Skin cancer risk classification lacks reliability for darker skin tones and fails in evaluating cutaneous medical conditions or cosmetic interventions, according to creators of the scale.

Earlier this week, we shared our third Rosacea Awareness Month quiz. Review the answers and your responses below.

A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.

A cross-sectional study revealed an increase and heightened prevalence of Demodex and demodicosis in individuals with psoriasis receiving biologic therapy.

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.

Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.

Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.

In online discussion April 23, commissioners cited health care specifically among their reasons for supporting the ban.

A review found that Mohs micrographic surgery and conventional excision yielded comparable patient reported outcomes.